Volume 10, Number 4—April 2004
Research
Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs
Emily L.C. Tan*, Eng Eong Ooi†, Chin-Yo Lin*, Hwee Cheng Tan†, Ai Ee Ling‡, Bing Lim*, and Lawrence W. Stanton*
Table 3
Complete inhibition of cytopathic effect (CIA100) at different virus titers
| Virus load (PFU/well) | Ribavirin (μg/mL) | Wellferon (IU/mL) | Betaferon (IU/mL) | Alferon (IU/mL) |
|---|---|---|---|---|
| 10,000 |
10,000 |
500,000 |
10,000 |
10,000 |
| 1,000 |
10,000 |
5,000 |
1,000 |
1,000 |
| 100 | 1,000 | 500 | 10 | 100 |
Page created: February 09, 2011
Page updated: February 09, 2011
Page reviewed: February 09, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.